Abstract:Abstract Background Respiratory Syncytial Virus (RSV)-related disease poses an economic burden due to a substantial amount of health care utilization (HCU). RENOIR is a phase 3 global, multicenter, randomized, double-blinded, placebo-controlled study evaluating vaccine efficacy (VE) in adults ≥60 years of age during two RSV seasons in Northern and Southern Hemisphere countries (Argentina, Canada, Finland, Japan, Netherlands, South Africa, and USA) (NCT05035212). VE at the end of the first RSV surveillance season (EOS1) against ARI-RSV, Lower Respiratory Tract Illness (LRTI)-RSV with ≥2 symptoms (2+ LRTI-RSV), and LRTI-RSV with ≥3 symptoms (3+ LRTI-RSV) was 62.2% (44.4, 74.9), 65.1% (35.9, 82.0), and 88.9% (53.6, 98.7), respectively. Methods HCU data and concomitant corticosteroid or antibiotic use were collected during the RSV season for Acute Respiratory Illness (ARI) events (defined as more than 1 day of new or increased cough, nasal congestion/discharge, sore throat, wheezing, sputum production, or shortness of breath). A pre-planned analysis of HCU at EOS1 was performed to assess HCU among participants receiving RSVpreF vs. placebo. Results A higher proportion of RSV-associated HCU was associated with more severe symptoms (43.0%, 60.3%, and 75% for ARI-RSV, 2+ LRTI-RSV, and 3+ LRTI-RSV, respectively). Medically attended (MA) VE was similar to VE for all first-episode cases with MA ARI-RSV 65.1% (35.9, 82.0), MA 2+ LRTI-RSV 70.4% (33.0, 88.4), MA 3+ LRTI-RSV 84.6% (32.0, 98.3). Most RSV-associated HCU were outpatient visits, with more in the placebo arm. A higher proportion of placebo arm participants with RSV cases had an RSV-associated emergency room visit. For ARI-RSV, there were 3 hospitalizations in the placebo arm and none in the RSVpreF arm. The placebo arm had higher antibiotic (11.8 - 55.6% higher) or corticosteroid (2.8 – 44.4% higher) use compared to the RSVpreF arm for ARI- or LRTI-RSV events. Table 1 Vaccine Efficacy of RSVpreF Against First Episode of RSV Cases in the First RSV Season – Evaluable Efficacy Population Table 2 Healthcare Resource Utilization Associated With RSV Cases in the First RSV Season Table 3 Prespecified Category of Concomitant Medication Uses for RSV Cases in the First RSV Season Conclusion RSVpreF reduced overall HCU and antibiotic or corticosteroid treatment for RSV-associated illnesses. The highest VE among MA RSV-associated cases was for MA 3+ LRTI-RSV. These findings suggest that RSVpreF may reduce RSV-related healthcare needs in older adults, thus alleviating this burden on health systems. Disclosures Edward E. Walsh, MD, Icosavax: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Merck: Honoraria|Moderna: Advisor/Consultant|Pfizer: Grant/Research Support Kumar Ilangovan, MD, MSPH, MMCi, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Agnieszka Zareba, MD PhD, Pfizer: Employee|Pfizer: Stocks/Bonds|Pfizer: Stocks/Bonds Qin Jiang, PhD, Pfizer: Employee|Pfizer: Employee|Pfizer: Stocks/Bonds|Pfizer: Stocks/Bonds Gonzalo Pérez Marc, M.D., GSK: Grant/Research Support|Merck: Grant/Research Support|Moderna: Expert Testimony|Moderna: Grant/Research Support|Pfizer: Grant/Research Support Elliot N. DeHaan, MD, Pfizer: Employee|Pfizer: Stocks/Bonds Michael Patton, B.Sc., Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds Yanqing Kan, MS, Pfizer: Pfizer's employee|Pfizer: Stocks/Bonds Daniel P. Eiras, MD, MPH, Pfizer, Inc.: Stocks/Bonds Tarek Mikati, MD,MPH, Pfizer: Stocks/Bonds Elena Kalinina, PhD, Pfizer: Pfizer employee|Pfizer: Stocks/Bonds David Cooper, PhD, Pfizer, Inc.: Stocks/Bonds Annaliesa S. Anderson, PhD, Pfizer: Employee|Pfizer: Stocks/Bonds Kena A. Swanson, Ph.D., Pfizer: Employee|Pfizer: Stocks/Bonds William C. Gruber, MD, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Alejandra C. Gurtman, M.D., Pfizer: Employee|Pfizer: Stocks/Bonds Beate Schmoele-Thoma, MD, Pfizer: Stocks/Bonds

Short-Term Immunogenicity of Licensed Subunit RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Compared to Community-Dwelling Older Adults

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

LB748. Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study

Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level

Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults

#11 Development of a Kinetic ELISA (kELISA) and Reactive B Cell Frequency (RBF) Assay to Detect Respiratory Syncytial Virus (RSV) Pre-Fusion F Protein-Specific Immune Responses in Infants

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study

1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)

Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study

Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein–based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial

Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults